United-Guardian Inc

United-Guardian Inc maintains a strong liquidity position, with a current ratio of 7.31, indicating a robust ability to meet short-term obligations. The company's liquidity_fpt score is high, supported by $1,251,100 in cash and equivalents and no long-term debt. This liquidity profile is further reinforced by a debt-to-equity ratio of 0.0, suggesting a conservative capital structure with no leverage risk.

Profitability metrics show United-Guardian Inc outperforms the median for its industry. The company's return on equity (ROE) of 18.75% and return on assets (ROA) of 16.06% are well above the typical benchmarks for pharmaceutical firms, indicating efficient use of equity and assets to generate returns. Gross margin of 48.75% (calculated from gross profit of $5,141,140 on revenue of $10,545,470) and operating margin of 21.28% (calculated from operating income of $2,243,350) also suggest strong cost control and pricing power.

The company's revenue is concentrated in a few key segments, with the majority derived from personal care products and pharmaceutical excipients. While the input data does not provide a detailed breakdown of geographic exposure, the company's operations are primarily U.S.-based, with limited international presence. This concentration may expose the company to regional economic or regulatory shifts.

Looking ahead, United-Guardian Inc is projected to maintain a stable growth trajectory. The company's revenue outlook for the current fiscal year is flat, with a marginal increase expected in the following year. Historical revenue growth has been modest, and the company's capital expenditure of $59,000 suggests a conservative approach to reinvestment. The free cash flow of -$611,780 indicates that the company is currently investing more in operations than it is generating, which may limit its ability to return capital to shareholders in the near term.

Risk factors for United-Guardian Inc are minimal in the short term, with no immediate filing-based liquidity or dilution flags detected. The company's dilution risk is low, as there is no indication of upcoming share issuance or convertible instruments. However, the company's reliance on a limited number of product lines and geographic markets could pose medium-term risks if demand shifts or regulatory changes occur.

Recent filings and transcripts do not highlight any material events or strategic shifts. The company's operations remain stable, with no significant changes in management or capital structure disclosed in the latest available documents.